+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioid Drugs: Global Markets to 2023

  • ID: 4702376
  • Report
  • Region: Global
  • 147 Pages
  • BCC Research
1 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Egalet Corp.
  • Indivior Plc
  • Kempharm Inc.
  • Mallinckrodt
  • Pernix Therapeutics
  • MORE

The current report offers a detailed picture of the prescription opioid drug market. Prescription opioids are included in the scope of study; illegal opioids such as heroin, which is sold in the illegal market for illicit usage, are not included. The market estimation includes all branded and generic opioid drugs indicated for different therapeutic application such as pain management and opioid use disorders.

This report highlights the current and future market potential of opioid drugs along with detailed analyses of the competitive environment, regulatory scenario, pipeline analysis, technological advancement, and market dynamics.

The report details market shares of opioid drugs based on product and geography. Based on product, the market is segmented into buprenorphine, fentanyl, hydrocodone, morphine, oxycodone, tramadol, and others. Each product segment includes detailed analyses covering an overview of the drug, mechanism of action and market insights on each drug.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. Detailed analyses of major countries such as the U.S., Germany, U.K. France, Japan, China, and India are covered in regional segments. For market estimates, data has been provided for the year 2017 and the base year of 2018 and forecast for 2023. Estimated values used are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

The Report Includes:

  • 20 data tables and 38 additional tables
  • An overview of the global market for opioid drugs
  • Analyses of global market trends, with data from 2017 to 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Discussion of types, mode of action and receptor target of opioids drugs i.e. Mu receptor, Delta receptor, and Kappa receptor
  • Details of technological advancement for the new opioid formulation to reduce the risk of drug abuse
  • A case study of opioid addiction, opioid abuse and overdose and significant events addressing opioid misuse and abuse
  • Information on stringent regulatory policies and government guidelines to impede the adoption rate of the opioid drugs
  • Insights of new safety measures announced for immediate release (IR) opioids and CDC guidelines on prescribing opioids for chronic pain
  • Company profiles of the major players of the market, including Acura Pharmaceuticals Inc., Cipher Pharmaceutical Inc., Daiichi Sankyo Inc., Johnson & Johnson, Lupin Ltd., Pfizer Inc., Sun Pharmaceuticals and Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Egalet Corp.
  • Indivior Plc
  • Kempharm Inc.
  • Mallinckrodt
  • Pernix Therapeutics
  • MORE

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Overview: Opioid Drugs
  • Types of Opioids
  • Receptor Targets of Opioid Drugs
  • Mu Receptor
  • Delta Receptor
  • Kappa Receptor
  • Significant Events Related to Opioid Misuse and Abuse
  • Technology Advancements in Opioid Drugs
  • Abuse-Deterrent Approaches
  • Abuse-Deterrent Technologies
  • Novel Drug Delivery Systems
  • Therapeutic Applications of Opioid Drugs
  • Cancer Pain Management
  • Surgical Pain Management
  • Opioid Use Disorder
  • Prescription Drug Monitoring Programs (PDMPs)

Chapter 4 Market Dynamics

  • Market Drivers
  • Rising Prevalence of Chronic Pain
  • Rise in Palliative Care for Patients Suffering from Pain
  • New Opioid Formulation to Reduce the Risk of Abuse
  • Increasing Incidence of Road Accidents and Surgical Procedures
  • Market Restraints
  • Widespread Misuse of Opioids
  • Increasing Incidence of Death Related to Opioid Overdose
  • Growing Number of Lawsuits against Opioid Manufacturers

Chapter 5 Market Breakdown by Product

  • Global Market for Opioid Drugs by Product
  • Buprenorphine
  • Market Size and Forecast
  • Market Analysis
  • Fentanyl
  • Market Size and Forecast
  • Market Analysis
  • Hydrocodone
  • Market Size and Forecast
  • Market Analysis
  • Morphine
  • Market Size and Forecast
  • Market Analysis
  • Oxycodone
  • Market Size and Forecast
  • Market Analysis
  • Tramadol
  • Market Size and Forecast
  • Market Analysis
  • Others
  • Market Size and Forecast
  • Market Analysis

Chapter 6 Market Breakdown by Region

  • Global Market for Opioid Drugs by Region
  • North America
  • United States
  • Canada and Mexico
  • Europe
  • Germany
  • U.K.
  • France
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • South America
  • Market Size and Forecast
  • Market Analysis
  • Middle East and Africa
  • Market Size and Forecast
  • Market Analysis

Chapter 7 Regulatory Environment

  • Regulations in the U.S.
  • New Drug Approvals
  • The FDA Modernization Act of 1997
  • New Safety Measures for Immediate-Release (IR) and Extended-Release (ER) Formulations
  • Risk Evaluation and Mitigation Strategy (REMS)
  • Schedules Under the Controlled Substances Act
  • Federal Initiatives to Address Non-medical Use of Prescription Opioids
  • FDA's Opioid Policy Work Plan
  • CDC Guidelines for Prescribing Opioids for Chronic Pain

Chapter 8 Pipeline Analysis

  • Overview of the Drug Development Process
  • Pipeline Analysis of Opioid Drugs

Chapter 9 Competitive Landscape

  • Current Market Scenario
  • Key Strategies Adopted by Market Players
  • Influence of Generic Drugs on the Global Opioid Drug Market
  • Significant Industry Events and Developments

Chapter 10 Company Profiles

  • ACURA PHARMACEUTICALS INC.
  • Company Overview
  • Product Portfolio
  • ALLERGAN PLC
  • Company Overview
  • Financials
  • Product Portfolio
  • APOTEX INC.
  • Company Overview
  • Product Portfolio
  • ASSERTIO THERAPEUTICS INC. (DEPOMED INC.)
  • Company Overview
  • Financials
  • Product Portfolio
  • Developments and Strategies
  • BIODELIVERY SCIENCES INTERNATIONAL INC.
  • Company Overview
  • Financials
  • Product Portfolio
  • Developments and Strategies
  • CIPHER PHARMACEUTICALS INC.
  • Company Overview
  • Product Portfolio
  • COLLEGIUM PHARMACEUTICAL INC.
  • Company Overview
  • Product Portfolio
  • DAIICHI SANKYO INC.
  • Company Overview
  • Product Portfolio
  • EGALET CORP.
  • Company Overview
  • Product Portfolio
  • ENDO INTERNATIONAL PLC
  • Company Overview
  • Financials
  • Product Portfolio
  • Developments and Strategy
  • HIKMA PHARMACEUTICALS PLC
  • Company Overview
  • Product Portfolio
  • INDIVIOR PLC
  • Company Overview
  • INSYS THERAPEUTICS INC.
  • Company Overview
  • Product Portfolio
  • JOHNSON & JOHNSON
  • Company Overview
  • Product Portfolio
  • KEMPHARM INC.
  • Company Overview
  • Product Portfolio
  • LANNETT CO. INC.
  • Company Overview
  • Financials
  • Product Portfolio
  • LUPIN LTD.
  • Company Overview
  • Product Portfolio
  • MALLINCKRODT
  • Company Overview
  • Product Portfolio
  • MYLAN NV
  • Company Overview
  • Financials
  • Product Portfolio
  • Developments and Strategies
  • OREXO AB
  • Company Overview
  • Product Portfolio
  • PFIZER INC.
  • Company Overview
  • Product Portfolio
  • Developments and Strategies
  • PURDUE PHARMA LP
  • Company Overview
  • Product Portfolio
  • Developments and Strategies
  • PERNIX THERAPEUTICS
  • Company Overview
  • Product Portfolio
  • Developments and Strategies
  • SUN PHARMACEUTICAL INDUSTRIES LTD. (SUN PHARMA)
  • Company Overview
  • Financials
  • Product Portfolio
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • Company Overview
  • Financials
  • Product Portfolio

Chapter 11 Appendix: Acronyms

List of Tables
Summary Table: Global Opioid Drug Market, by Product, Through 2023
Table 1: Analgesic Effects of Drugs at Different Opioid Receptors
Table 2: Timeline of Selected FDA Activities and Events Related to Opioid Misuse and Abuse, 1911-2018
Table 3: FDA Approved Opioids with ADF Labeling
Table 4: Opioid Lawsuit Settlements, 2015-2027
Table 5: Global Opioid Drug Market, by Product, Through 2023
Table 6: Global Buprenorphine Drug Market, by Region, Through 2023
Table 7: Global Fentanyl Drug Market, by Region, Through 2023
Table 8: Global Hydrocodone Drug Market, by Region, Through 2023
Table 9: Global Morphine Drug Market, by Region, Through 2023
Table 10: Global Oxycodone Drug Market, by Region, Through 2023
Table 11: Global Tramadol Drug Market, by Region, Through 2023
Table 12: Global Market for Other Types of Opioid Drugs, by Region, Through 2023
Table 13: Global Opioid Drug Market, by Region, Through 2023
Table 14: North American Opioid Drug Market, by Product, Through 2023
Table 15: North American Opioid Drug Market, by Country, Through 2023
Table 16: Number of Prescriptions for Six of the Most Frequently Prescribed Opioids in Canada, 2012-2016
Table 17: European Opioid Drug Market, by Product, Through 2023
Table 18: European Opioid Drug Market, by Country, Through 2023
Table 19: Asia-Pacific Opioid Drug Market, by Product, Through 2023
Table 20: Asia-Pacific Opioid Drug Market, by Country, Through 2023
Table 21: South American Opioid Drug Market, by Product, Through 2023
Table 22: Middle East and African Opioid Drug Market, by Product, Through 2023
Table 23: List of ER/LA Opioid Drugs Subject to Opioid REMS, Branded Drugs, 2017
Table 24: List of ER/LA Opioid Drugs Subject to Opioid REMS, Generic Drugs, 2017
Table 25: Schedules Under the Controlled Substances Act
Table 26: Recent Initiatives to Control the Opioid Crisis in the U.S., 2018
Table 27: CDC Guidelines on Prescribing Opioids
Table 28: Opioid Drug Pipeline
Table 29: R&D Expenditures of Market Players, 2017
Table 30: Number of FDA Approvals (NDA and ANDA), 2005-2015
Table 31: Significant Industry Events in the Opioid Drug Market, 2015-2018
Table 32: Acura Pharmaceuticals: Opioid Drug Product Portfolio
Table 33: Allergan Plc: Opioid Drug Product Portfolio
Table 34: Apotex Inc.: Opioid Drug Product Portfolio
Table 35: Assertio Therapeutics: Opioid Drug Product Portfolio
Table 36: Biodelivery Sciences International Inc.: Opioid Drugs Product Portfolio
Table 37: Cipher Pharmaceuticals Inc.: Opioid Drugs Product Portfolio
Table 38: Collegium Pharmaceutical Inc.: Opioid Drug Product Portfolio
Table 39: Daiichi Sankyo Inc.: Opioid Drug Product Portfolio
Table 40: Egalet Corp.: Opioid Drugs Product Portfolio
Table 41: Endo International Plc: Opioid Drugs Product Portfolio
Table 42: Hikma Pharmaceuticals Plc: Opioid Drugs Product Portfolio
Table 43: Indivior Plc: Opioid Drug Product Portfolio
Table 44: Insys Therapeutics Inc.: Opioid Drug Product Portfolio
Table 45: Johnson & Johnson: Opioid Drug Product Portfolio
Table 46: KemPharm Inc.: Opioid Drugs Product Portfolio
Table 47: Lannett Co. Inc.: Opioid Drug Product Portfolio
Table 48: Lupin Ltd.: Opioid Drug Product Portfolio
Table 49: Mallinckrodt: Opioid Drug Product Portfolio
Table 50: Mylan NV: Opioid Drug Product Portfolio
Table 51: Orexo AB: Opioid Drug Product Portfolio
Table 52: Pfizer Inc.: Opioid Drugs Product Portfolio
Table 53: Purdue Pharma LP: Opioid Drug Product Portfolio
Table 54: Pernix Therapeutics: Opioid Drug Product Portfolio
Table 55: Sun Pharmaceuticals Industries Ltd.: Opioid Drugs Product Portfolio
Table 56: Teva Pharmaceutical Industries Ltd.: Opioid Drug Product Portfolio
Table 57: Acronyms Used in This Report

List of Figures
Summary Figure: Global Opioid Drug Market Share, by Product, 2017
Figure 1: Opioid Misuse Among People 12 or Older, by Age Group, 2015
Figure 2: Prescription Pain Relief Misuse Among People 12 or Older, by Age Group, 2015
Figure 3: Number of Drug Overdose Deaths in the U.S., 2010-2016
Figure 4: Global Opioid Drug Market Share, by Product, 2017
Figure 5: Global Buprenorphine Drug Market, 2017-2023
Figure 6: Global Buprenorphine Drug Market, by Region, 2017-2023
Figure 7: Global Fentanyl Drug Market, 2017-2023
Figure 8: Global Fentanyl Drug Market, by Region, 2017-2023
Figure 9: Global Hydrocodone Drug Market, 2017-2023
Figure 10: Global Hydrocodone Drug Market, by Region, 2017-2023
Figure 11: Global Morphine Drug Market, 2017-2023
Figure 12: Global Morphine Drug Market, by Region, 2017-2023
Figure 13: Global Oxycodone Drug Market, 2017-2023
Figure 14: Global Oxycodone Drug Market, by Region, 2017-2023
Figure 15: Global Tramadol Drug Market, 2017-2023
Figure 16: Global Tramadol Drug Market, by Region, 2017-2023
Figure 17: Global Market for Other Types of Opioid Drugs, 2017-2023
Figure 18: Global Market for Other Types of Opioid Drugs, by Region, 2017-2023
Figure 19: Global Opioid Drug Market Share, by Region, 2017
Figure 20: North American Opioid Drug Market Share, by Product, 2017
Figure 21: North American Opioid Drug Market Share, by Country, 2017
Figure 22: U.S. Opioid Drug Market, 2017-2023
Figure 23: Total Number of Opioid Prescriptions Dispensed, U.S, 2010-2017
Figure 24: Number of Drug Overdose Deaths, U.S., 2010-2016
Figure 25: Canadian and Mexican Market for Opioid Drugs, 2017-2023
Figure 26: European Opioid Drug Market Share, by Product, 2017
Figure 27: European Opioid Drug Market Share, by Country, 2017
Figure 28: German Opioid Drug Market, 2017-2023
Figure 29: U.K. Opioid Drug Market, 2017-2023
Figure 30: French Opioid Drug Market, 2017-2023
Figure 31: Rest of European Market for Opioid Drugs, 2017-2023
Figure 32: Asia-Pacific Opioid Drug Market Share, by Product, 2017
Figure 33: Asia-Pacific Opioid Drug Market Share, by Country, 2017
Figure 34: Japanese Opioid Drug Market, 2017-2023
Figure 35: Chinese Opioid Drug Market, 2017-2023
Figure 36: Indian Opioid Drug Market, 2017-2023
Figure 37: Rest of Asia-Pacific Opioid Drug Market, 2017-2023
Figure 38: South American Opioid Drug Market, 2017-2023
Figure 39: South American Opioid Drug Market Share, by Product, 2017
Figure 40: Middle East and African Market for Opioid Drugs, 2017-2023
Figure 41: Middle East and African Opioid Drug Market Share, by Product, 2017
Figure 42: Allergan Plc: Annual Revenue, 2013-2017
Figure 43: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 44: Assertio Therapeutics: Revenue, 2013-2017
Figure 45: Biodelivery Sciences International Inc.: Annual Revenue, 2013-2017
Figure 46: Endo International Plc: Revenue, 2013-2017
Figure 47: Endo International Plc: Revenue Share, by Business Unit, 2017
Figure 48: Lannett Co. Inc.: Financial Performance, 2015-2017
Figure 49: Mylan NV: Financial Performance, 2014-2017
Figure 50: Mylan NV: Revenue Share, by Region, 2017
Figure 51: Sun Pharmaceuticals Industries Ltd.: Financial Performance, 2015-2017
Figure 52: Teva Pharmaceutical Industries Ltd.: Financial Performance, 2015-2017
Figure 53: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Region, 2017
Figure 54: Teva Pharmaceutical Industries Ltd.: Revenue Share, by Business Segment, 2016

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Allergan Plc
  • Egalet Corp.
  • Indivior Plc
  • Kempharm Inc.
  • Mallinckrodt
  • Pernix Therapeutics
  • MORE

The growth of the global market is attributed to the factors such as the growing prevalence of cancer, high demand for pain therapeutics in the treatment of chronic pain, regulatory approvals and launches of innovative drug formulations, and growing approval rate of abuse-deterrent formulations of opioid drugs.

The opioid drug market is a fragmented market with numerous small and large players. Market players are investing in the development of novel therapeutics, which is anticipated to drive the market during the forecast period.

The global opioid drug market is segmented based on the product and region.

Note: Product cover images may vary from those shown
5 of 6
  • Acura Pharmaceuticals Inc.
  • Allergan Plc
  • Apotex Inc.
  • Assertio Therapeutics Inc. (Depomed Inc.)
  • Biodelivery Sciences International Inc.
  • Cipher Pharmaceuticals Inc.
  • Collegium Pharmaceutical Inc.
  • Daiichi Sankyo Inc.
  • Egalet Corp.
  • Endo International Plc
  • Hikma Pharmaceuticals Plc
  • Indivior Plc
  • Insys Therapeutics Inc.
  • Johnson & Johnson
  • Kempharm Inc.
  • Lannett Co. Inc.
  • Lupin Ltd.
  • Mallinckrodt
  • Mylan Nv
  • Orexo Ab
  • Pernix Therapeutics
  • Pfizer Inc.
  • Purdue Pharma Lp
  • Sun Pharmaceutical Industries Ltd. (Sun Pharma)
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4702376
Adroll
adroll